Mashup Score: 4
www.foxchase.orgPHILADELPHIA (February 15, 2023)—Half of the experimental group of muscle-invasive bladder cancer patients successfully kept their bladders and reached the two-year endpoint of the RETAIN BLADDER phase II clinical trial without developing metastatic cancer, according to final results presented today by Fox Chase Cancer Center researchers at the 2023 American Society of Clinical Oncology...
The concept of bladder preservation has increasing significance in localized MIBC. Clinical trials like RETAIN play an important role in biomarker validation assessment. Despite not meeting the primary endpoint, this trial paved the way for similar trials in this therapy setting.